BIO Share Price

Open 27.94 Change Price %
High 27.98 1 Day 0.12 0.43
Low 27.80 1 Week -0.12 -0.43
Close 27.98 1 Month 8.43 43.12
Volume 17691 1 Year 10.99 64.69
52 Week High 28.60
52 Week Low 15.44
BIO Important Levels
Resistance 2 28.15
Resistance 1 28.08
Pivot 27.92
Support 1 27.88
Support 2 27.81
ETR Germany Most Active Stocks
DBK 17.34 2.36%
DBK 17.34 2.36%
CBK 9.07 0.22%
CBK 9.07 0.22%
EOAN 7.15 -1.11%
EOAN 7.15 -1.11%
DTE 16.40 -0.36%
DTE 16.40 -0.36%
DTE 16.40 -0.36%
DTE 16.40 -0.36%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
ECX 7.12 43.84%
ECX 7.12 43.84%
I8R 73.22 14.93%
5M71 39.00 13.70%
RPL 24.77 12.69%
RPL 24.77 12.69%
LTEC 31.91 10.19%
C1V 3.37 8.36%
EV4 1.94 7.78%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
ARO 0.01 -50.00%
ARO 0.01 -50.00%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
AYO 0.02 -33.33%
USX1 21.71 -25.03%
FAM1 1.15 -15.44%
More..

Biotest AG (ETR: BIO)

BIO Technical Analysis 5
As on 26th Apr 2017 BIO Share Price closed @ 27.98 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 17.91 & Strong Buy for SHORT-TERM with Stoploss of 21.72 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO Target for April
1st Target up-side 29.44
2nd Target up-side 32.14
3rd Target up-side 34.84
1st Target down-side 21.74
2nd Target down-side 19.04
3rd Target down-side 16.34
BIO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO Address
BIO
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.